

Contents

List of Contributors xvii

Preface xxi

1 Utilization of Synthetic Drugs in Cancer: Preclinical and Clinical-based Evidence 1

Sandeep Vaidya, Avadh Biharee, Arpita Yadav, Arun Kumar Sharma, Akhlesh Kumar Jain, Suresh Thareja, and Mayank Kumar Singh

- 1.1 Introduction 1
- 1.1.1 Cancer Biology and Pathophysiology 2
- 1.1.2 Nanomedicine in Cancer Treatments 3
- 1.1.2.1 Applications of Nanomedicine in Cancer Treatment 5
- 1.1.3 Evolution of Synthetic Anticancer Drugs from Ancient Beliefs to Modern Medicine 6
- 1.2 Synthetic Pharmaceutical Anticancer Drugs 8
- 1.3 Challenges Faced in Early Drug Development 17
- 1.4 Conclusion 20
- Acknowledgments 21
- References 21

2 United States and European Union Regulations: Approved Treatment Modalities for Managing Cancer 29

Avadh Biharee, Khushi Gupta, Arpita Yadav, Shivam Kumar kori, Sudha Bhartiya, Kashif sheikh, Sandeep Vaidya, Sushil K. Kashaw, Suresh Thareja, and Mayank Kumar Singh

- 2.1 Introduction 29
- 2.2 FDA Strategies for Drug Approval in the United States 31
- 2.2.1 Expedited Approval of Anticancer Drugs in the United States 32
- 2.3 EMA Approach for Drug Approval in the EU 35
- 2.3.1 Expedited Anticancer Drug Approval in EU 36

2.4	Approved Treatment Modalities for Cancer Care	38
2.4.1	Conventional Cancer Therapy	39
2.4.2	Innovative Cancer Treatments	40
2.4.3	Physical Therapy for Cancer Treatment	41
2.4.4	Personalized and Precision Medicine	42
2.5	Quality Control in Cancer Treatment	43
2.6	Regulatory Frameworks Involved in Drug Approval Process	44
2.6.1	FDA and EMA Approach to Drug Approval for Cancer Treatment	45
2.6.1.1	Drug Approval in the United States	46
2.6.1.2	Drug Approval in the EU	46
2.6.2	Key Differences in the FDA and the EU Drug Approval Processes	48
2.6.3	Comparison of the United States and the EU Device Approval	50
2.7	Challenges Associated in Drug and Devices Regulation and Approval	52
2.8	Conclusion	53
	Acknowledgments	54
	References	54

3 Survival Rate and Associated Side Effects of Synthetic Drugs in Cancer Patients: A Shred of Clinical Evidence 63

Arpita Yadav, Arun Kumar Sharma, Kishan Kumar Pandey, Anu Chaudhary, Avadh Biharee, Sandeep Vaidya, Suresh Thareja, and Mayank Kumar Singh

3.1	Introduction	63
3.2	Synthetic Drugs in Cancer Treatment	65
3.3	The Evolution of Chemotherapeutic Agents from Alkylators to Modern Drugs	66
3.4	Cancer Survival Rates: Challenges and Emerging Trends in Treatment and Diagnosis	68
3.4.1	Targeted Therapies and Immunotherapies: The New Cancer Treatments	69
3.4.2	Factors Affecting Survival Rates	70
3.5	Deleterious Effects of Chemotherapeutic Agents and Their Management Strategies	72
3.6	Side Effects of Synthetic Drugs	74
3.6.1	Short-term Side Effects	74
3.6.2	Long-term Side Effects	75
3.7	Clinical Evidence of Side Effects	76
3.8	Resistance and Recurrence	76
3.9	Future Directions of Synthetic Drugs Against Various Types of Cancer	77
3.10	Conclusion	78

Acknowledgments 79

References 79

4 Global Perspectives on Plant-derived Cancer Therapies 91

Sayanta Sarkar and Poorwa Awasthi

4.1 Introduction 91

4.2 Phytochemicals in Cancer Therapies 92

4.2.1 *Rosmarinus officinalis L.* 93

4.2.2 *Withania somnifera* 95

4.2.3 *Hedychium coronarium* 97

4.2.4 *Catharanthus roseus* 99

4.2.5 *Ocimum sanctum* 100

4.2.6 *Piper betle* 102

4.3 Phytochemicals in Drug-resistant Cancers 103

4.4 Plant-based Nanomedicines in Cancer Therapies 103

4.5 Conclusion and Future Perspectives 104

References 106

5 Integrative Approaches: Combining Conventional and Plant-derived Cancer Therapies 119

Poorwa Awasthi, Shweta Goyal, and Sayanta Sarkar

5.1 Introduction 119

5.2 Conventional Cancer Therapies: Achievements and Limitations 120

5.3 Plant-derived Compounds in Cancer Therapy 124

5.3.1 Bioactive Molecules and Their Mechanisms 124

5.3.1.1 Polyphenols 124

5.3.1.2 Alkaloids 124

5.3.1.3 Terpenoids 125

5.4 Advantages of Natural Products 125

5.5 Synergistic Potential of Combination Therapies 128

5.5.1 Mechanisms of Synergy 128

5.5.2 Common Examples of Cancer with Combination Therapies 128

5.5.2.1 Breast Cancer 129

5.5.2.2 Lung Cancer 130

5.5.2.3 Colorectal Cancer 131

5.5.2.4 Prostate Cancer 132

5.5.2.5 Ovarian Cancer 133

5.5.2.6 Leukemia 135

5.5.2.7 Liver Cancer 136

5.5.2.8 Brain Cancer 138

5.6 Challenges and Future Perspectives 140

- 5.7 Conclusion 142
- References 143

6 Phytochemical Drugs in Cancer: Therapeutic Interventions and Opportunities 159

Archana Kumari, Shankar Suman, and Shivam Priya

- 6.1 Introduction 159
- 6.2 Plant-derived Compounds in Cancer Therapy 160
 - 6.2.1 Alkaloids and Their Anticancer Effects 161
 - 6.2.2 Terpenoids as Potent Anticancer Agents 161
 - 6.2.3 Flavonoids: Multifunctional Cancer Fighters 161
- 6.3 Mechanisms of Action of Plant-derived Compounds 162
 - 6.3.1 Induction of Apoptosis 162
 - 6.3.2 Targeting CSCs 162
 - 6.3.3 Antiangiogenic Properties 163
 - 6.3.4 Inhibition of Metastasis and Tumor Progression 163
- 6.4 Nanotechnology in Enhancing Plant-derived Compounds 164
 - 6.4.1 Improving Bioavailability and Stability Through Nanoparticle Encapsulation 164
 - 6.4.2 Targeted Delivery and Reduced Side Effects of Plant-derived Compounds 164
 - 6.4.3 Overcoming Multidrug Resistance with Nanotechnology 164
- 6.5 Clinical Trials and Research on Plant-derived Anticancer Compounds 165
 - 6.5.1 Clinical Trials of Curcumin in Cancer Therapy 165
 - 6.5.2 Paclitaxel and Semisynthetic Taxanes 165
 - 6.5.3 Flavonoids in Clinical Studies 166
- 6.6 Challenges and Future Directions in Plant-derived Cancer Therapies 166
 - 6.6.1 Issues with Bioavailability and Solubility 166
 - 6.6.2 Standardization and Quality Control 166
 - 6.6.3 Clinical Validation and Regulatory Challenges 166
 - 6.6.4 Potential of Bioinformatics in Drug Discovery 167
- 6.7 Advanced Applications of Bioinformatics in Plant-based Drug Discovery 168
 - 6.7.1 Molecular Docking Studies and Predictive Modeling 168
 - 6.7.2 Network Pharmacology Approaches 168
 - 6.7.3 Genomics and Metabolomics in Identifying Novel Compounds 169
- 6.8 Case Studies of Successful Plant-derived Cancer Therapies 169
 - 6.8.1 Green Tea Extracts in Clinical Applications 169
 - 6.8.2 Vinca Alkaloids in Clinical Applications 169

- 6.8.3 Resveratrol's Potential in Cancer Therapy 170
- 6.9 Future Perspectives and Integration into Clinical Oncology 171
- 6.9.1 Development of Combination Therapies 171
- 6.9.2 Role of Personalized Medicine 171
- 6.9.3 Advanced Drug Delivery Systems 171
- 6.10 Conclusion and Future Directions 172
- References 174

7 Plant-derived Anticancer Molecules as Novel Outlook in the Management of Cancers: An *In silico* and Pharmacophore-based Approaches 183

Surya Venkateswara Prabhu Ratnam Kesanapalli, Babli K. Jha, and Laxmi Devi

- 7.1 Introduction 183
- 7.2 Historical Perspective 184
- 7.3 Key Discoveries of Plant-derived Anticancer Compounds 184
- 7.4 Phytochemicals with Anticancer Properties 185
 - 7.4.1 Alkaloids 185
 - 7.4.2 Flavonoids 186
 - 7.4.3 Terpenes 187
 - 7.4.3.1 Paclitaxel (Taxol) 187
 - 7.4.3.2 Limonene 187
 - 7.4.3.3 Phenolics 187
 - 7.4.3.4 Polyphenols 187
 - 7.4.3.5 Saponins 188
 - 7.4.3.6 Lignans 188
 - 7.5 Computational Approaches in Phytochemical Research 188
 - 7.5.1 *In silico* Docking Analysis 189
 - 7.5.2 Virtual Screening 190
 - 7.5.3 Quantitative Structure-Activity Relationship 190
 - 7.5.4 Structure-based Screening Method 191
 - 7.5.5 Molecular Dynamics Simulations 192
 - 7.5.6 Cheminformatics 192
 - 7.5.7 Pharmacophore Modeling 192
 - 7.5.8 ML and AI in Drug Discovery 193
 - 7.6 Novel Therapeutic Approaches 193
 - 7.6.1 Phytochemical-based Drug Formulations 193
 - 7.6.2 Immunotherapy 194
 - 7.6.3 Targeted Therapy 194
 - 7.6.4 Nano Catalysts 194
 - 7.6.5 Combination Therapies 194

7.6.6	Personalized Medicine	195
7.6.7	Advanced Drug Delivery Systems	195
7.7	Challenges and Future Directions	196
7.8	Bioavailability Issues	196
7.9	Regulatory Hurdles	196
7.9.1	Ethical Considerations and Sustainable Sourcing	197
7.10	Advancements in Computational Power and Algorithms	197
7.10.1	Quantum Computing	197
7.10.2	Explainable AI	198
7.10.3	Precision Oncology	199
7.10.4	Biomarker Discovery	199
7.11	Conclusion	200
	Acknowledgment	201
	References	202

8 Plant-derived Molecules and Herbal Formulation for Cancer Treatment: *in vitro* and *in vivo* Evidence 209

Surya Venkateswara Prabhu Ratnam Kesanapalli, Babli K. Jha, and Laxmi Devi

8.1	Introduction	209
8.2	Historical Use of Herbal Remedies in Cancer	210
8.3	Natural Compounds with Anticancer Properties	211
8.3.1	Alkaloids	212
8.3.2	Flavonoids	214
8.3.3	Terpenoids	214
8.3.4	Polyphenols	215
8.3.5	Saponins	215
8.3.6	Lignans	215
8.4	Mechanism of Action	215
8.5	Natural Remedies in Cancer Treatment	216
8.6	Phototherapeutic Approaches in Oncology Care	218
8.7	Methodological Approaches	220
8.7.1	<i>In silico</i> Studies (Computational Approaches)	220
8.7.2	Network Pharmacology	221
8.7.3	<i>In vitro</i> Studies (Cell-based Assays)	221
8.7.3.1	Cytotoxicity Assays (MTT, Trypan Blue, LDH Assay)	221
8.7.3.2	Lactate Dehydrogenase Release Assay	221
8.7.4	Apoptosis and Cell Cycle Analysis	221
8.7.5	Caspase Activation Assays	221
8.7.6	Proliferation and Migration Assays	221

8.7.6.1	Bromodeoxyuridine or 5-Ethynyl-2'-deoxyuridine Incorporation Assays	221
8.7.6.2	Scratch Wound Healing Assay	222
8.7.7	Caco-2 Permeability Assay	222
8.7.8	Western Blot and Reverse Transcription-Polymerase Chain Reaction	222
8.7.9	Wound Healing and Transwell Migration Assays	222
8.8	<i>In vivo</i> Studies (Animal Models)	222
8.8.1	Xenograft Models	222
8.8.2	Genetically Engineered Mouse Models	222
8.8.3	Toxicity and Pharmacokinetics Studies	222
8.8.4	Xenograft Tumor Models	222
8.8.5	GEMMs in Drug Resistance Studies	223
8.8.6	Patient-derived Xenograft Models	223
8.9	Ex Vivo and 3D Models	224
8.9.1	Patient-derived Organoids	224
8.9.2	3D Spheroid Cultures	224
8.10	Clinical Trials and Translational Research	224
8.10.1	Phases I-III Clinical Trials	224
8.10.2	Combination Therapy Studies	224
8.11	Nanotechnology-based Delivery Systems	224
8.12	Experimental Validation of Computational Predictions	224
8.12.1	Machine Learning and Artificial Intelligence in Drug Discovery	225
8.12.2	Biophysical and Biochemical Binding Assays	225
8.12.3	Advanced Experimental Approaches	226
8.12.4	Immunomodulatory Approaches	226
8.12.5	Pharmacophore-based Approaches	226
8.12.5.1	Targeting Specific Interactions	226
8.12.5.2	Guiding Virtual Screening	227
8.12.5.3	Enhancing Lead Optimization	227
8.12.5.4	Reducing False Positives/Negatives	227
8.13	Key Findings	228
8.14	Challenges and Future Directions	228
8.14.1	Challenges in Standardization and Bioavailability	228
8.14.2	Natural Compounds for Supportive Cancer Care	228
8.15	Future Studies and Clinical Trials	229
8.16	Conclusion	229
	Acknowledgment	229
	References	230

9 Globalization of Plant-derived Molecules Against Progression and Metastasis of Cancer in the Last Few Decades 239

Kavita, Praveen Kumar, Shikha Singh, and Neha Garg

- 9.1 Introduction 239
- 9.2 Plant-derived Molecules in Cancer 240
 - 9.2.1 Alkaloids 240
 - 9.2.1.1 Camptothecin 240
 - 9.2.1.2 Berberine 251
 - 9.2.1.3 Evodiamine 251
 - 9.2.1.4 Sanguinarine 252
 - 9.2.1.5 Matrine 252
 - 9.2.1.6 Piperine 253
 - 9.2.1.7 Vinblastine and Vincristine 253
 - 9.2.1.8 Tetrandrine 253
 - 9.2.2 Polyphenols 254
 - 9.2.2.1 Flavonoids 254
 - 9.2.2.2 Phenolic Acids 259
 - 9.2.2.3 Stilbenes 259
 - 9.2.2.4 Lignans 260
 - 9.2.3 Taxanes and Epipodophyllotoxins 261
 - 9.2.3.1 Paclitaxel 261
 - 9.2.3.2 Docetaxel 261
 - 9.2.4 Glycosides 262
 - 9.2.4.1 Rutin 262
 - 9.2.4.2 Verbascoside 262
 - 9.2.4.3 Russelloside 262
- 9.3 Conclusion and Future Perspectives 263
 - List of Abbreviations 263
 - Conflict of Interest 263
 - Acknowledgment 264
 - References 264

10 Quantum Dots for Targeted Delivery of Plant-derived Anticancer Biomolecules 279

Rashmi P. Sharma

- 10.1 Introduction 279
- 10.2 Quantum Dots: A Promising Nanomaterial 283
 - 10.2.1 Types of QDs 283
 - 10.2.1.1 Core-type QDs 284
 - 10.2.1.2 Core-shell QDs 284

- 10.2.1.3 Alloyed QDs 284
- 10.2.2 Advantageous Properties of QDs for Targeted Drug Delivery 285
- 10.3 Cellular Delivery of Cancer-targeting QDs 286
- 10.4 Recent Developments in Using QD-based Targeted Drug Delivery 288
 - 10.4.1 Taxanes 290
 - 10.4.2 Alkaloids 291
 - 10.4.3 Polyphenols 293
 - 10.4.4 Flavonoids 295
 - 10.4.5 Other Plant-derived Anticancerous Compounds 296
- 10.5 Challenges and Future Perspectives 297
- 10.6 Conclusions 299
 - References 299

11 Future of Artificial Intelligence and Plant-derived Molecules in Cancer Therapy 313

Jyotika Rajawat, Shreya Prakash, and Poorwa Awasthi

- 11.1 Introduction 313
- 11.2 Plant-derived Molecules in Cancer Therapy 315
 - 11.2.1 Camptothecin 315
 - 11.2.2 Taxol 316
 - 11.2.3 Anthocyanins 316
 - 11.2.4 Phytosphingosine 317
 - 11.2.5 Genistein 317
- 11.3 Natural Plant Extracts with Potential as Anticancer Agents 319
 - 11.3.1 *Fagonia indica* 320
 - 11.3.2 *Aristolochia baetica* 320
 - 11.3.3 *Catharanthus roseus* 321
 - 11.3.4 *Curcuma longa* 322
 - 11.3.5 *Artemisia annua* 322
- 11.4 AI in Cancer Diagnosis and Treatment 323
- 11.5 Role of AI in Advancing Plant-derived Molecules for Cancer Therapy 327
 - 11.5.1 High-throughput Screening of Phytochemicals 327
 - 11.5.2 Toxicity Prediction and ADMET Profiling 328
 - 11.5.3 Target Identification and Validation 330
 - 11.5.4 Optimization of Drug Design 331
 - 11.5.5 Drug Repurposing 332
- 11.6 Future Perspectives 332
 - References 333

12 Scientific Basis of Plant-derived Quantum Dots for Enhancing the Therapeutic Efficacy in Cancer 341

Lucky Kumari, Shashi Kumar, Chandramani Batsh, Shachi Mishra, and Akanksha Upadhyay

- 12.1 Introduction 341
- 12.2 Classification of QDs 344
- 12.3 Synthesis of Plant-derived QDs 346
 - 12.3.1 Hydrothermal Method 347
 - 12.3.2 Microwave Method 348
 - 12.3.3 Chemical Oxidation Method 348
 - 12.3.4 Pyrolysis Method 349
- 12.4 Plant-derived QDs in Cancer Diagnosis and Therapy 352
 - 12.4.1 *In vitro* Cytotoxicity 352
 - 12.4.2 *In vivo* Cytotoxicity 353
- 12.5 Therapeutic Efficacy 354
 - 12.5.1 Photo-induced Cancer Treatment 355
 - 12.5.2 Gene Therapy 356
 - 12.5.3 Immunotherapy 357
- 12.6 Conclusion and Future Perspectives 359
- References 360

13 Clinical Trials of Plant-derived Molecules and Herbal Formulations for the Treatment of Cancers 367

Ankur Kumar

- 13.1 Introduction 367
- 13.2 Clinical Trials of Curcumin 368
- 13.3 Clinical Trials of Catechin and Tea 373
- 13.4 Clinical Trials of Quercetin 379
- 13.5 Clinical Trials of Ginseng Extract 380
- 13.6 Clinical Trials of Genistein 381
- 13.7 Clinical Trial of Resveratrol 382
- 13.8 Clinical Trials of Sulforaphane 383
- 13.9 Clinical Trials of Berberine 384
- 13.10 Clinical Trials of Lycopene 385
- 13.11 Clinical Trials of Chinese Herbal Formulation 386
- 13.12 Clinical Trials of Other Herbal Formulation 393
- 13.13 Clinical Trials of Rutin 395
- 13.14 Clinical Trials of Betulinic Acid 395
- Competing Interest 396
- References 396

14 Preclinical and Clinical Trials of Plant-derived Nanoparticles in Different Cancers 401*Vivek Kumar Pandey and Shailja Tripathi*

- 14.1 Introduction 401
- 14.2 Synthesis of Plant-derived Nanoparticles 402
- 14.2.1 Advantages of Plant-derived Nanoparticles 404
- 14.3 PDNPs in Cancers 405
 - 14.3.1 Plant-derived Nanoparticles in Cancer Treatment 406
 - 14.3.2 Advantages of Plant-derived Nanoparticles in Cancer Treatment 409
 - 14.3.3 PDNPs' Mechanisms of Action in Cancer Therapy 409
 - 14.3.4 Plant-derived Nanoparticles in Cancer Therapy 410
 - 14.3.5 PDNPs in Clinical Trials for Cancer Treatment 411
- 14.4 PDNPs in Other Metabolic Diseases 411
- 14.5 Challenges and Future Directions 413
- References 414

Index 427

